Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aplitabart + FOLFIRI + bevacizumab
- Development stage
- Unknown
- Lead developer
- IGM Biosciences
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This drug regimen is a combination therapy that includes **aplitabart** (a monoclonal antibody under investigation for cancer), **FOLFIRI** (a chemotherapy regimen consisting of folinic acid/leucovorin, fluorouracil, and irinotecan), and **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A). This triple combination is designed for enhanced anti-tumor effects, leveraging: - aplitabart for immune modulation (precise mechanism is under research), - FOLFIRI for cytotoxic activity primarily used in metastatic colorectal cancer, - bevacizumab for anti-angiogenesis by inhibiting VEGF-A. The combination is being studied for advanced solid tumors, particularly metastatic colorectal cancer.
- Other names
- leucovorin + fluorouracil + irinotecan + aplitabart + bevacizumab
02
Targets
TNFRSF10B (DR5)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on aplitabart + FOLFIRI + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aplitabart + FOLFIRI + bevacizumab.